Angiotensin II in Liver Transplantation
Active, not recruiting · Phase 2, Phase 3 · NCT04901169
Conditions: Liver Transplant, Complications, Vasoplegia
At a glance
- Research payments reported, 2025
- $7,060
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- University of California, San Francisco (with La Jolla Pharmaceutical Company)
- Tested
- Angiotensin II (drug), Saline (drug)
- Dates
- Started 2022-06-28; completion 2027-03-18
- Results posted
- Not yet
The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.
From ClinicalTrials.gov, last updated 2026-03-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $7,060 in research payments for this study in 2025 (1 payments).
Products named: Giapreza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.